DOCSLIB.ORG

Cyanokit Label

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyanokit Label HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use -------------------------------CONTRAINDICATIONS----------------------------- Cyanokit safely and effectively. See full prescribing information for None (4) Cyanokit. ------------------------WARNINGS AND PRECAUTIONS----------------------- Cyanokit® (hydroxocobalamin for injection) 5 g for intravenous use • Use caution in the management of patients with known anaphylactic Initial U.S. Approval: 1975 reactions to hydroxocobalamin or cyanocobalamin. Consideration should be given to use of alternative therapies, if available. (5.2) ----------------------------INDICATIONS AND USAGE--------------------------- • Allergic reactions may include: anaphylaxis, chest tightness, edema, Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment urticaria, pruritus, dyspnea, and rash. (5.2) of known or suspected cyanide poisoning. (1.1) • Blood pressure increase: Substantial increases in blood pressure may • If clinical suspicion of cyanide poisoning is high, Cyanokit should be occur following Cyanokit therapy. (5.3) administered without delay. (1.2) • The expert advice of a regional poison control center may be obtained by -------------------------------ADVERSE REACTIONS------------------------------ calling 1-800-222-1222. (1.2) Most common adverse reactions (>5%) include transient chromaturia, erythema, rash, increased blood pressure, nausea, headache, and injection site ------------------------DOSAGE AND ADMINISTRATION---------------------- reactions. (6) • The starting dose of Cyanokit for adults is 5 g, (two 2.5 g vials) administered by IV infusion over 15 minutes. (2.1) To report SUSPECTED ADVERSE REACTIONS contact Dey, L.P. at • Depending upon the severity of the poisoning and the clinical response, a 1-800-429-7751, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. second dose of 5 g may be administered by IV infusion for a total dose of 10 g. (2.1) ------------------------USE IN SPECIFIC POPULATIONS---------------------- • The rate of infusion for the second 5 g dose may range from 15 minutes No safety and efficacy studies have been performed in pediatric patients. (8.4) (for patients in extremis) to 2 hours based on patient condition. (2.1) • The recommended diluent is 0.9% Sodium Chloride injection. (2.2) • Diluent is not included with Cyanokit. (2.2) See 17 for PATIENT COUNSELING INFORMATION And FDA- • There are a number of drugs and blood products that are incompatible Approved Patient Labeling. with Cyanokit, thus Cyanokit may require a separate intravenous line for Revised: 12/2006 administration. (2.3) -----------------------DOSAGE FORMS AND STRENGTH---------------------- Cyanokit 5 g consists of 2 vials, each with 2.5 g lyophilized hydroxocobalamin dark red crystalline powder for injection. (3) After reconstitution, each vial contains hydroxocobalamin for injection, 25 mg/mL. (3) FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 10 OVERDOSAGE 1.1 Indication 11 DESCRIPTION 1.2 Identifying Patients with Cyanide Poisoning 12 CLINICAL PHARMACOLOGY 1.3 Use with Other Cyanide Antidotes 12.1 Mechanism of Action 2 DOSAGE AND ADMINISTRATION 12.2 Pharmacodynamics 2.1 Recommended Dosing 12.3 Pharmacokinetics 2.2 Preparation of Solution for Infusion 13 NONCLINICAL TOXICOLOGY 2.3 Incompatibility Information 13.1 Carcinogenesis, Mutagenesis, Impairment of 2.4 Storage of Reconstituted Drug Product Fertility 3 DOSAGE FORMS AND STRENGTHS 13.2 Animal Pharmacology 4 CONTRAINDICATIONS 14 CLINICAL STUDIES 5 WARNINGS AND PRECAUTIONS 14.1 Smoke Inhalation Victims 5.1 Emergency Patient Management 14.2 Cyanide Poisoning by Ingestion or Inhalation 5.2 Allergic Reactions 14.3 Cross-Study Findings 5.3 Blood Pressure Increase 16 HOW SUPPLIED/STORAGE AND HANDLING 5.4 Use of Blood Cyanide Assay 17 PATIENT COUNSELING INFORMATION 5.5 Interference with Clinical Laboratory 17.1 Erythema and Chromaturia Evaluations 17.2 Rash 5.6 Photosensitivity 17.3 Breast Feeding 6 ADVERSE REACTIONS 17.4 FDA-Approved Patient Labeling 6.1 Clinical Studies Experience 7 DRUG INTERACTIONS * Sections or subsections omitted from the full prescribing information are not 8 USE IN SPECIFIC POPULATIONS listed. 8.1 Pregnancy 8.2 Labor and Delivery 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment FULL PRESCRIBING INFORMATION supplied sterile transfer spike. The recommended diluent is 0.9% Sodium 1 INDICATIONS AND USAGE Chloride injection (0.9% NaCl). Lactated Ringers injection and 5% Dextrose 1.1 Indication injection (D5W) have also been found to be compatible with Cyanokit is indicated for the treatment of known or suspected hydroxocobalamin and may be used if 0.9% NaCl is not readily available. cyanide poisoning. The line on each vial label represents 100 mL volume of diluent. Following 1.2 Identifying Patients with Cyanide Poisoning the addition of diluent to the lyophilized powder, each vial should be Cyanide poisoning may result from inhalation, ingestion, or dermal repeatedly inverted or rocked, not shaken, for at least 30 seconds prior to exposure to various cyanide-containing compounds, including smoke from infusion. closed-space fires. Sources of cyanide poisoning include hydrogen cyanide Hydroxocobalamin solutions should be visually inspected for and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to particulate matter and color prior to administration. If the reconstituted sodium nitroprusside. solution is not dark red or if particulate matter is seen after the solution has The presence and extent of cyanide poisoning are often initially been appropriately mixed, the solution should be discarded. unknown. There is no widely available, rapid, confirmatory cyanide blood 2.3 Incompatibility Information test. Treatment decisions must be made on the basis of clinical history and Physical incompatibility (particle formation) was observed with the signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide mixture of hydroxocobalamin in solution and the following drugs: diazepam, poisoning is high, Cyanokit should be administered without delay. dobutamine, dopamine, fentanyl, nitroglycerin, pentobarbital, propofol, and thiopental. Consequently, these drugs should not be administered Table 1 Common signs and Symptoms of Cyanide Poisoning simultaneously through the same IV line as hydroxocobalamin. Symptoms Signs Chemical incompatibility was observed with sodium thiosulfate, • Headache • Altered Mental Status sodium nitrite, and has been reported with ascorbic acid. Consequently, these • Confusion (e.g., confusion, disorientation) drugs should not be administered simultaneously through the same IV line as • Dyspnea • Seizures or Coma hydroxocobalamin. • Chest • Mydriasis Simultaneous administration of hydroxocobalamin and blood tightness • Tachypnea / Hyperpnea (early) products (whole blood, packed red cells, platelet concentrate and/or fresh • Nausea • Bradypnea / Apnea (late) frozen plasma) through the same IV line is not recommended. However, • Hypertension (early) / Hypotension (late) blood products and hydroxocobalamin can be administered simultaneously using separate IV lines (preferably on contralateral extremities, if peripheral • Cardiovascular collapse lines are being used). • Vomiting 2.4 Storage of Reconstituted Drug Product • Plasma lactate concentration ≥8 mmol/L Once reconstituted, hydroxocobalamin is stable for up to 6 hours at temperatures not exceeding 40°C (104°F). Do not freeze. Any reconstituted In some settings, panic symptoms including tachypnea and vomiting product not used by 6 hours should be discarded. may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of 3 DOSAGE FORMS AND STRENGTHS true cyanide poisoning although these signs can occur with other toxic Cyanokit 5 g consists of 2 vials, each containing 2.5 g lyophilized exposures as well. hydroxocobalamin dark red crystalline powder for injection. After The expert advice of a regional poison control center may be obtained reconstitution, each vial contains hydroxocobalamin for injection, 25 mg/mL. by calling 1-800-222-1222. Administration of both vials constitutes a single dose. [See How Smoke Inhalation Supplied/Storage and Handling (16) for full kit description.] Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances 4 CONTRAINDICATIONS making a diagnosis of cyanide poisoning particularly difficult. Prior to None administration of Cyanokit, smoke-inhalation victims should be assessed for the following: 5 WARNINGS AND PRECAUTIONS • Exposure to fire or smoke in an enclosed area 5.1 Emergency Patient Management • Presence of soot around the mouth, nose or oropharynx In addition to Cyanokit, treatment of cyanide poisoning must include • Altered mental status immediate attention to airway patency, adequacy of oxygenation and hydration, cardiovascular support, and management of any seizure activity. Although hypotension is highly suggestive of cyanide poisoning, it is Consideration should be given to decontamination measures based on the only present in a small percentage of cyanide-poisoned smoke inhalation route of exposure. victims. Also indicative of cyanide poisoning is a plasma lactate 5.2 Allergic Reactions concentration ≥10 mmol/L (a value higher than that typically listed in the Use caution in the
Load more

Recommended publications
  • Significance and Implications of Vitamin B-12 Reaction Shema- ETH ZURICH VARIANT: Mechanisms and Insights
    Taylor University Pillars at Taylor University Student Scholarship: Chemistry Chemistry and Biochemistry Fall 2019 Significance and Implications of Vitamin B-12 Reaction Shema- ETH ZURICH VARIANT: Mechanisms and Insights David Joshua Ferguson Follow this and additional works at: https://pillars.taylor.edu/chemistry-student Part of the Analytical Chemistry Commons, Inorganic Chemistry Commons, Organic Chemistry Commons, Other Chemistry Commons, and the Physical Chemistry Commons CHEMISTRY THESIS SIGNIFICANCE AND IMPLICATIONS OF VITAMIN B-12 REACTION SCHEMA- ETH ZURICH VARIANT: MECHANISMS AND INSIGHTS DAVID JOSHUA FERGUSON 2019 2 Table of Contents: Chapter 1 6 Chapter 2 17 Chapter 3 40 Chapter 4 59 Chapter 5 82 Chapter 6 118 Chapter 7 122 Appendix References 3 Chapter 1 A. INTRODUCTION. Vitamin B-12 otherwise known as cyanocobalamin is a compound with synthetic elegance. Considering how it is composed of an aromatic macrocyclic corrin there are key features of this molecule that are observed either in its synthesis of in the biochemical reactions it plays a role in whether they be isomerization reactions or transfer reactions. In this paper the focus for the discussion will be on the history, chemical significance and total synthesis of vitamin B12. Even more so the paper will be concentrated one of the two variants of the vitamin B-12 synthesis, namely the ETH Zurich variant spearheaded by Albert Eschenmoser.Examining the structure as a whole it is observed that a large portion of the vitamin B12 is a corrin structure with a cobalt ion in the center of the macrocyclic part, and that same cobalt ion has cyanide ligands.
    [Show full text]
  • IV-23 N. Hydroxocobalamin (Cyanokit®)
    N. Hydroxocobalamin (Cyanokit®) I. Classification •Cyanide antidote II. Actions •Binds cyanide ions with more affinity than hemoglobin molecule •Cyanide ion and hydroxocobalamin form cyanocobalamin (Vitamin B12) which is then excreted in the urine. III. Indications •Known or suspected cyanide poisoning - patients at high risk (industrial accidents, fire victims with smoke inhalation, known overdose, etc) with one more more of the following symptoms: - Altered mental status, confusion, seizures, coma - Headache - Chest pain or tightness - Shortness of breath, bradypnea, tachypnea - Hypertension (early), hypotension (late), cardiovascular collapse - Nausea, vomiting - Cardiac arrest - Mydriasis (dilated pupils) IV. Contraindications •Known allergic reaction to hydroxocobalamin or cyanocobalamin V. Adverse effects A. Cardiovascular •Ventricular extrasystoles •Tachycardia •Transient hypertension B. Neurological •Memory impairment •Dizziness •Restlessness C. Respiratory •Dyspnea •Dry Throat •Throat tightness D. Gastrointestinal •Abdominal discomfort •Dysphagia •Vomiting, diarrhea •Hematochezia E. General •Allergic reaction, pruritis, anaphylaxis •Hot flush SUBJECT : PATIENT CARE GUIDELINES AND STANDING ORDERS FOR BLS AND ALS UNITS REFERENCE NO. III-01 PUBLICATION : 1/11/21 IV-23 VI. Administration A. Do not administer hydroxocobalamin through the same IV site/set as the following medications: dopamine, fentanyl, dobutamine, diazepam, nitroglycerin, pentobarbital, propofol, thiopental, sodium thiosulfate, sodium nitrite and ascorbic acid. You must start a second IV to administer hydroxocobalamin in patient’s receiving these medications. B. Adult: •5 grams IV/IO over 15 minutes (Stocked as single 5gm bottle, or two 2.5 gm bottles) -Single 5 gm Bottle - Reconstituted with 200 ml Normal Saline. -Two 2.5 gm Bottles, give over 7.5 minutes each. - Each vial reconstituted with 100 ml Normal Saline. C. Pediatric •100 mg/kg IV/IO of hydroxocobalamin (reconstituted with Normal Saline the same as adults) over 15 minutes.
    [Show full text]
  • Cyanocobalamin-A Case for Withdrawal
    686 Journal of the Royal Society of Medicine Volume 85 November 1992 Cyanocobalamin- a case for withdrawal: discussion paper A G Freeman MD FRCP Meadow Rise, 3 Lakeside, Swindon SN3 IQE Keywords: anaemia, pernicious; optic neuropathies; chronic cyanide intoxication; hydroxocobalamin; cyanocobalamin It seems evident that controversy still surrounds the reduced ability to detoxify the cyanide in the tobacco- treatment of pernicious anaemia and other vitamin smoke to which they are exposed'0. B12 deficiency disorders. The long quest for the 'anti- Patients with tobacco amblyopia who have normal pernicious anaemia factor' in the liver seemed to serum vitamin B12 levels need not continue therapy have ended in 1948 when pure cyanocobalamin was with intramuscular hydroxocobalamin once their isolated. This was found to be very active thera- visual acuity and visual fields have returned to peutically when given by intramuscular injection and normal providing they abstain from further smoking. was non-toxic in extremely high doses'. However, those patients who have low serum vitamin Lederle, in a recent commentary2, advocates that B12 levels or evidence of -defective vitamin B12 patients with pernicious anaemia should now be absorption will need to continue-indefinitely with treated with oral cyanocobalamin. He is not without hydroxocobalamin irrespective of their smoking support in that 40% of patients with pernicious habits as will all patients with pernicious anaemia anaemia in Sweden are being similarly treated3. and other vitamin B12 deficiency disorders who are He further states that such!- treatment is cheap at risk of developing- optic neuropathy if they and effective, produces clinical and haematological are smokers.
    [Show full text]
  • Magnesium-Protoporphyrin Chelatase of Rhodobacter
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 1941-1944, March 1995 Biochemistry Magnesium-protoporphyrin chelatase of Rhodobacter sphaeroides: Reconstitution of activity by combining the products of the bchH, -I, and -D genes expressed in Escherichia coli (protoporphyrin IX/tetrapyrrole/chlorophyll/bacteriochlorophyll/photosynthesis) LUCIEN C. D. GIBSON*, ROBERT D. WILLOWSt, C. GAMINI KANNANGARAt, DITER VON WETTSTEINt, AND C. NEIL HUNTER* *Krebs Institute for Biomolecular Research and Robert Hill Institute for Photosynthesis, Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, S10 2TN, United Kingdom; and tCarlsberg Laboratory, Department of Physiology, Gamle Carlsberg Vej 10, DK-2500 Copenhagen Valby, Denmark Contributed by Diter von Wettstein, November 14, 1994 ABSTRACT Magnesium-protoporphyrin chelatase lies at Escherichia coli and demonstrate that the extracts of the E. coli the branch point of the heme and (bacterio)chlorophyll bio- transformants can convert Mg-protoporphyrin IX to Mg- synthetic pathways. In this work, the photosynthetic bacte- protoporphyrin monomethyl ester (20, 21). Apart from posi- rium Rhodobacter sphaeroides has been used as a model system tively identifying bchM as the gene encoding the Mg- for the study of this reaction. The bchH and the bchI and -D protoporphyrin methyltransferase, this work opens up the genes from R. sphaeroides were expressed in Escherichia coli. possibility of extending this approach to other parts of the When cell-free extracts from strains expressing BchH, BchI, pathway. In this paper, we report the expression of the genes and BchD were combined, the mixture was able to catalyze the bchH, -I, and -D from R. sphaeroides in E. coli: extracts from insertion of Mg into protoporphyrin IX in an ATP-dependent these transformants, when combined in vitro, are highly active manner.
    [Show full text]
  • Thiosulfate De Sodium Sterop
    Thiosulfate de Sodium Sterop 1. DENOMINATION DU MEDICAMENT THIOSULFATE DE SODIUM STEROP 1g/5ml solution injectable 2. COMPOSITION QUALITATIVE ET QUANTITATIVE Substance active : Une ampoule de 5ml contient 1g de thiosulfate de sodium dans de l’eau pour préparations injectables. 1 ml de solution contient 200mg de thiosulfate de sodium. Pour la liste complète des excipients, voir rubrique 6.1. 3. FORME PHARMACEUTIQUE Solution injectable. 4. DONNEES CLINIQUES 4.1 Indications thérapeutiques - Antidote dans le traitement des intoxications par les cyanures ainsi que par le nitroprussiate de sodium. - Prévention des effets néphrotoxiques du cisplatine. Thiosulfate de Sodium Sterop © Pharma.be Pagina 1 van 6 4.2 Posologie et mode d’administration Mode d'administration Pour voie intraveineuse lente. Posologie Intoxications par les cyanures: Adultes: La posologie habituelle est de 12,5 g de thiosulfate de sodium, administré par voie I.V. sur une période de 5 à 10 minutes. Enfants: La posologie habituelle est de 412,5 mg de thiosulfate de sodium par kg, administré par voie I.V. à la vitesse de 0,625 à 1,25 g/minute sur une période de 5 à 10 minutes. Si les symptômes persistent ou réapparaissent dans la demi-heure ou dans l’heure ayant suivi la première injection, une seconde injection de thiosulfate de sodium est nécessaire avec comme posologie la moitié de celle de la première injection. En prévention des effets néphrotoxiques du cisplatine: Chez l'adulte, la posologie initiale est de 9 g de thiosulfate de sodium par m2 de surface corporelle, administré par voie I.V. Elle est suivie par l'injection de 1,2 g de thiosulfate de sodium par m2 de surface corporelle par heure, en perfusion I.V.
    [Show full text]
  • Hydroxocobalamin for Injection) for Intravenous Infusion Alternative Therapies, If Available, in Patients with Known Anaphylactic Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------CONTRAINDICATIONS----------------------------- These highlights do not include all the information needed to use None (4) CYANOKIT safely and effectively. See full prescribing information for CYANOKIT. ------------------------WARNINGS AND PRECAUTIONS----------------------- Risk of Anaphylaxis and Other Hypersensitivity Reactions: Consider CYANOKIT® (hydroxocobalamin for injection) for intravenous infusion alternative therapies, if available, in patients with known anaphylactic Initial U.S. Approval: 1975 reactions to hydroxocobalamin or cyanocobalamin. (5.2) Risk of Renal Injury: Acute renal failure with acute tubular necrosis, renal ----------------------------RECENT MAJOR CHANGES-------------------------- impairment and urine calcium oxalate crystals have been reported Warnings and Precautions, Risk of Renal Injury (5.3) 12/2018 following CYANOKIT therapy. Monitor renal function for 7 days Warnings and Precautions, Use of Blood Cyanide Assay (5.7) 12/2018 following CYANOKIT therapy. (5.3) Risk of Increased Blood Pressure: Substantial increases in blood pressure ----------------------------INDICATIONS AND USAGE--------------------------- may occur following CYANOKIT therapy. Monitor blood pressure during CYANOKIT is indicated for the treatment of known or suspected cyanide treatment. (5.4) poisoning. (1) -------------------------------ADVERSE REACTIONS------------------------------ ------------------------DOSAGE AND ADMINISTRATION---------------------- Most common
    [Show full text]
  • Adult BLS Standing Orders • Ensure EMS Provider Safety, Consider HAZMAT Activation
    Imperial County Public Health Department Emergency Medical Services Agency Policy/Procedure/Protocol Manual Treatment Protocols Date: 07/01/2021 Poisoning/Intoxication/Envenomation - Adult Policy #9160A Adult BLS Standing Orders • Ensure EMS provider safety, consider HAZMAT activation. Recognize, Notify, Isolate • Universal Patient Protocol • Do not approach patient or location if scene safety is in question • Obtain accurate history of incident: o Name of product or substance o Quantity ingested, and/or duration of exposure o Time elapsed since exposure o If safe and accessible, bring medications or bottles to hospital • Move victim(s) to safe environment • Externally decontaminate - PRN • Continuously monitor ECG, blood pressure, pulse oximetry, and capnography (if ALS present) PRN • Give oxygen and provide airway support per Airway Policy • Contact Poison Control Center as needed 1 (800) 222-1222 Suspected Opioid Overdose with Respirations <12 RPM • If possible, avoid the use of a supraglottic device prior to the administration of naloxone • Administer naloxone 0.1 mg/kg, max of 2 mg IN. May repeat up to three (3) times, q5min • May assist family/friends on-scene with administration of patient’s own naloxone • NOTE - Use with caution in opioid dependent pain management patients • Assess vitals, with specific attention to respiratory rate and respiratory drive • Note pupil exam • Note drug paraphernalia or medication bottles near patient Suspected Stimulant Overdose with Sudden Hypoventilation, Oxygen Desaturation, or Apnea • High flow
    [Show full text]
  • Hydrogen Sulfide Metabolite, Sodium Thiosulfate
    International Journal of Molecular Sciences Review Hydrogen Sulfide Metabolite, Sodium Thiosulfate: Clinical Applications and Underlying Molecular Mechanisms Max Y. Zhang 1,2, George J. Dugbartey 1,2,3, Smriti Juriasingani 1,3 and Alp Sener 1,2,3,4,* 1 Matthew Mailing Center for Translational Transplant Studies, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada; [email protected] (M.Y.Z.); [email protected] (G.J.D.); [email protected] (S.J.) 2 London Health Sciences Center, Multi-Organ Transplant Program, Western University, London, ON N6A 5A5, Canada 3 London Health Sciences Center, Department of Surgery, Division of Urology, Western University, London, ON N6A 5A5, Canada 4 Department of Microbiology & Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada * Correspondence: [email protected]; Tel.: +1(519) 6633352 Abstract: Thiosulfate in the form of sodium thiosulfate (STS) is a major oxidation product of hydrogen sulfide (H2S), an endogenous signaling molecule and the third member of the gasotransmitter family. STS is currently used in the clinical treatment of acute cyanide poisoning, cisplatin toxicities in cancer therapy, and calciphylaxis in dialysis patients. Burgeoning evidence show that STS has antioxidant and anti-inflammatory properties, making it a potential therapeutic candidate molecule that can target multiple molecular pathways in various diseases and drug-induced toxicities. This review Citation: Zhang, M.Y.; Dugbartey, discusses the biochemical and molecular pathways in the generation of STS from H2S, its clinical G.J.; Juriasingani, S.; Sener, A. usefulness, and potential clinical applications, as well as the molecular mechanisms underlying these Hydrogen Sulfide Metabolite, clinical applications and a future perspective in kidney transplantation.
    [Show full text]
  • Ingestions, Intoxications, and the Critically Ill Child Poisoning in Children
    Ingestions, Intoxications, and the Critically Ill Child Poisoning in Children • 1 million cases of exposure to toxins in children younger than 6 years reported in the U.S. In 1993 • estimated that another 1 million exposures to toxins not reported • 1% have moderate or major life-threatening symptoms • 60-100 deaths annually in the U.S Poisoning in Children Less Than 5 Years Old • accounts for 85-90% of pediatric poisoning • is generally accidental • secondary to exploratory behavior and lack of supervision • tend to involve single agent ingestions Poisoning in Children Over 5 Years Old • accounts for 10-15% of pediatric poisoning • is generally intentional • secondary to suicide attempts or gestures, or to intoxications and inadvertent overdose • tend to involve multiple agent ingestions General Concepts for Pediatric Poisoning • Prevention • Initial Stabilization • Diagnosis • Specific Antidotes Management of the Poisoned Child • Treat the Patient, Not the Poison --patient-specific treatment is safer, less expensive, and more effective Management of the Poisoned Child • Stabilization --Airway --Breathing --Circulation --Disability (neurologic) Management of the Poisoned Child • Respiratory Failure --airway obstruction from secretions, refluxed gastric contents, airway muscle relaxation --respiratory muscle rigidity --loss of respiratory drive --pulmonary edema Management of the Poisoned Child • Cardiovascular Collapse --arteriolar dilation --venous dilation --myocardial depression --dysrhythmias Management of the Poisoned Child • Neurologic
    [Show full text]
  • Antidote List
    Antidote List Recommended minimum amounts for hospital pharmacies to stock Call the Maryland Poison Center for expert advice on the treatment of all poisonings and overdoses: 1-800-222-1222 Poisoning Minimum Stocking Antidote Indication Recommendations Oral: 120 grams Acetylcysteine Acetaminophen IV: 96 grams Crotaline snake Antivenin, snake (CroFab®) 12 vials envenomation 1 vial Black widow spider (Note: Merck limits distribution Antivenin, black widow spider envenomation to cases of confirmed bites with symptoms only) Organophosphate & Atropine carbamate insecticides, nerve 165 mg gases Calcium chloride Calcium channel blockers 10 grams 2.25 grams Calcium disodium EDTA Lead (Available direct from ASD Specialty Healthcare) Hydrofluoric acid 1 kg (powder) Calcium gluconate Calcium channel blockers IV: 30 grams 1 kit Cyanide Antidote Kit Cyanide (or Hydroxocobalamin, see below) Cyproheptadine (Periactin®) Serotonin syndrome 80 mg Neuroleptic malignant Dantrolene syndrome, stimulant-induced 720 mg hyperthermia Deferoxamine mesylate Iron 8 grams (Desferal®) Digoxin Immune FAB Digoxin 20 vials (Digibind®, DigiFab®) Dimercaprol (BAL) Heavy metals 1.5 grams 1 | P a g e Maryland Poison Center Antidote List – continued Poisoning Minimum Stocking Antidote Indication Recommendations DMSA (Succimer, Chemet®) Heavy metals 2000 mg Folic acid Methanol IV: 150 mg Flumazenil (Romazicon®) Benzodiazepines 10 mg Fomepizole (Antizol®) Ethylene glycol, methanol 12 grams Beta blockers, Glucagon 50 mg calcium channel blockers Hydroxocobalamin (Cyanokit®) Cyanide
    [Show full text]
  • 1 INTRODUCTION Corroles Are Tetrapyrrolic Molecules, Maintaining
    1 Chapter 1 INTRODUCTION Corroles are tetrapyrrolic molecules, maintaining the skeletal structure of corrin, with its three meso carbon positions and one direct pyrrole-pyrrole linkage, and possessing the aromaticity of porphyrins (see figure 1.1). First reported by Johnson and Kay in 1965[1], corroles were the end product of a many step synthetic scheme, finally being formed by the photocyclization of a,c-biladienes. While this last step was simple, with 20-60% yields, the route to a,c-biladienes was far from easy. Indeed, the overall reaction from readily available starting materials to corrole was a multi-step synthesis, with poor yields in many of the reactions. Thus, while corroles have been known for more than 40 years, research in the field was slow to progress. It wasn’t until the discovery of new synthetic methods for corroles developed in 1999 by different groups working independently that research in this area really started to expand[2]. This is not to say, however, that the field of corrole research was non-existent prior to the development of the new methodologies. While it was slow growing after the initial publication, it was far from stagnant, and many of the interesting properties of corroles were investigated by different groups. Among these properties is their ability to stabilize unusually high formal oxidation states of metal ions, such as iron(IV), cobalt(IV), and cobalt(V)[3, 4]. In fact, one particular corrole available through a method developed by Zeev 2 N N H N N H H N N N N a b N N H H H N N c Figure 1.1.
    [Show full text]
  • ABSTRACT ZHANG, SHAOFEI. Synthesis Of
    ABSTRACT ZHANG, SHAOFEI. Synthesis of Bacteriochlorins and the Full Skeleton of Bacteriochlorophylls. (Under the direction of Professor Jonathan S. Lindsey.) Bacteriochlorins, the core macrocycle ring of natural bacteriochlorophylls, are characterized by their ability to absorb near infrared light (700 – 900 nm), which makes them attractive candidates in variety of photophysical studies and applications. The previously established de novo synthesis, which relies on the acid-catalyzed self-condensation of dihydrodipyrrin–acetal, provides access towards diverse bacteriochlorins, but has its limitations. This dissertation describes the development of new strategies for bacteriochlorin synthesis. Firstly, a route towards previously unknown tetra-alkyl bacteriochlorins (e.g., alkyl = Me, or –CH2CO2Me) is established (Ch. 2). Secondly, explorations of synthetic approaches to unsymmetrically substituted bacteriochlorins through electrocyclic reactions of linear tetrapyrrole intermediates are described. Four new unsymmetrically substituted bacteriochlorins and one new tetradehydrocorrin were produced, albeit in low yields (Ch. 3). Thirdly, a new method to construct bacteriochlorin macrocycle with concomitant Nazarov cyclization to form the annulated isocyclic ring, is established. Five new bacteriochlorins, which are closely anlogues of bacteriochlorophyll a, bearing various substituents (alkyl/alkyl, aryl, and alkyl/ester) at positions 2 and 3 and 132 carboalkoxy groups (R = Me or Et) were constructed in 37−61% yield from the bilin analogues
    [Show full text]